What AMP® AIM Partners Are Saying

AbbVie

At AbbVie, we know that tackling the toughest healthcare challenges requires a dynamic and collaborative approach. We are excited to be involved in the next phase of the Accelerating Medicines Partnership program to build a more complete picture of rheumatoid arthritis, lupus, Sjögren’s disease, and other serious autoimmune diseases by implementing innovative technologies like spatial transcriptomics. This collaboration will enable the identification of novel targets and biomarkers to address the unmet needs of people living with autoimmune and immune-mediated diseases.”

Jonathon Sedgwick, Ph.D.
Vice President and Global Head of Discovery Research
AbbVie


Bristol Myers Squibb

Despite advances in our understanding of inflammatory and autoimmune diseases, there remains unmet need, particularly in identifying patients most likely to benefit from therapeutic interventions. We believe in the power of collaboration and are proud to have participated in the AMP RA/SLE Program to collectively explore difficult medical and scientific questions with the goal of advancing treatments for patients. We are even more pleased to continue this work with the AMP AIM Program by building on the RA/SLE experience and expanding to other important disease areas. We look forward to this partnership and the potential to uncover novel drug targets and precision medicine approaches that will benefit patients across the world."

Rupert Vessey, MA, BM, BCh, FRCP, DPhil
Executive Vice President and President, Research and Early Development
Bristol Myers Squibb


Janssen Research & Development, LLC

Truly difficult challenges require collaboration and Janssen is proud to support AMP in this next project to unravel the molecular drivers of immune-mediated disorders. This unique collaboration between the NIH, industry partners, and non-profit institutes brings together the necessary talent to unravel the molecular drivers of these devastating diseases and will pave the way for tomorrow’s medicines.”

David Lee, MD, PhD
Immunology Therapeutic Area Head
Janssen Research & Development, LLC


Lupus Foundation of America  

The Lupus Foundation of America and National Institutes of Health are committed in their shared goal to reducing the time to an accurate lupus diagnosis and ensuring people with lupus have access to newly targeted and safe treatments. Bold initiatives, like the AMP AIM program, seek to discover the causes of inflammation and clinical disease, and hold the promise for addressing the significant unmet need for people living with lupus and other autoimmune diseases.”

Stevan W. Gibson
President and CEO
Lupus Foundation of America


Lupus Research Alliance

The Lupus Research Alliance is proud to be part of AMP-AIM which will enable unprecedented disease characterization and novel target identification for lupus and related diseases. This important program builds on the pioneering discoveries of AMP RA/SLE and will provide further insights into disease mechanisms as well as critical clinical data sets and research tools to accelerate the development of novel therapies for individuals with lupus."

Teodora Staeva, Ph.D.
Chief Scientific Officer
Lupus Research Alliance


National Psoriasis Foundation

As the Accelerating Medicines Partnership (AMP AIM) expands to include psoriasis and psoriatic arthritis – systemic, inflammatory, immune-mediated diseases – the National Psoriasis Foundation looks forward to the answers that this robust initiative may generate. This next generation public-private partnership will enable discovery of new mechanisms and targets for novel intervention and treatment development, as well as an enhanced disease understanding for earlier diagnosis and improved management by leveraging collaboration and technical innovation. As the voice of the psoriatic disease community for five decades, NPF joins with excitement about the possibilities that AMP AIM holds to achieve the vision of a life free of psoriatic disease and the associated burdens."

Stacie Bell, Ph.D.
Chief Scientific and Medical Officer
National Psoriasis Foundation


Pfizer Inc.

Autoimmune diseases can be debilitating, disfiguring and distressing, dramatically affecting patients’ day-to-day lives. We are pleased to continue our partnership through AMP AIM to accelerate the discovery of innovative treatments and ultimately improve the lives of our patients.”

Mike Vincent
SVP and Chief Scientific Officer, Inflammation & Immunology Research Unit
Pfizer Inc.


Sanofi

We are excited to be part for the new AMP AIM program in immunological diseases. In the last 6 years the Accelerating Medicine Partnership has delivered valuable insights into the molecular and cellular mechanisms of Rheumatoid Arthritis and Systemic Lupus Erythematosus at single cell resolution. Building on these achievements, AMP AIM will help to understand shared and unique molecular mechanisms in a range of inflammatory diseases and will support our mission to deliver life changing medicines for the benefit of patients."

Frank Nestle
Global Head of Research
Sanofi


Sjögren’s Foundation

Sjögren’s is a systemic autoimmune disease that is frequently misunderstood and underdiagnosed. We are extremely proud to join the AMP AIM project as a Steering Committee member alongside the NIH, other disease advocacy organizations and pharmaceutical companies. AMP AIM offers a new way to tackle the formidable barriers that have prevented us from fully understanding Sjögren’s and will potentially uncover mysteries so we can better diagnose and treat Sjögren’s patients in the future.”

Janet Church
President and CEO
Sjögren’s Foundation


The Arthritis Foundation, Inc. 

The Arthritis Foundation is excited to continue being a stakeholder in the Accelerating Medicines Partnership (AMP). We are looking forward to contributing to the important work that will be done by the Autoimmune and Immune-Mediated Diseases Program, or AMP AIM. This collaborative research will further accelerate the validation of specific drug targets in autoimmune diseases that share immune and inflammatory pathways. It will facilitate both therapeutic development and data sharing through a knowledge portal, and further our Foundation’s mission of improving the lives of patients with various forms of arthritis, including rheumatoid arthritis.”

Maria Vassileva, Ph.D.
Senior Vice President, Science Strategy
Arthritis Foundation


UCB

UCB is proud to partner with the Foundation for the National Institutes of Health for their AMP Autoimmune and Immune-Mediated Diseases initiative. By leveraging state of the art technology and novel analytics to improve our understanding of tissue level cellular function, and its role in inflammation and clinical disease, this research will advance our understanding of costly diseases that place a high burden on patients, including disease progression from psoriasis to psoriatic arthritis, disease phenotypes and systemic lupus erythematosus (SLE). These collaborations are critical for speeding the development of innovative therapies that can significantly improve patients’ lives,’’

Dhaval Patel
Chief Scientific Officer
UCB

ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services